Several brokerages have updated their recommendations and price targets on shares of Autodesk (NASDAQ: ADSK) in the last few weeks: 8/21/2026 – Autodesk had its price target raised by Robert W. Baird from $312.00 to $325.00. They now have an “outperform” rating on the stock. 8/20/2026 – Autodesk was given a new $277.00 price target […]

Lumentum (NASDAQ: LITE) has recently received a number of price target changes and ratings updates: 8/21/2026 – Lumentum had its “outperform” rating reaffirmed by Wolfe Research. 8/20/2026 – Lumentum was upgraded by Zacks Research from “hold” to “strong-buy”. 8/19/2026 – Lumentum was downgraded by Weiss Ratings from “hold (c-)” to “sell (d-)”. 8/12/2026 – Lumentum […]

Duolingo (NASDAQ: DUOL) has recently received a number of price target changes and ratings updates: 8/25/2026 – Duolingo had its “hold” rating reaffirmed by Argus. They now have a $146.00 price target on the stock. 8/20/2026 – Duolingo had its price target raised by Wedbush from $139.00 to $150.00. They now have a “neutral” rating […]

Kura Oncology (NASDAQ: KURA) has recently received a number of price target changes and ratings updates: 8/24/2026 – Kura Oncology was given a new $24.00 price target by Raymond James Financial, Inc.. 8/24/2026 – Kura Oncology was given a new $24.00 price target by Morgan Stanley. 8/24/2026 – Kura Oncology had its “market outperform” rating […]

Zimmer Biomet (NYSE: ZBH) recently received a number of ratings updates from brokerages and research firms: 8/10/2026 – Zimmer Biomet had its price target raised by Canaccord Genuity Group Inc. from $83.00 to $100.00. They now have a “hold” rating on the stock. 8/8/2026 – Zimmer Biomet was downgraded by Wall Street Zen from “buy” […]

A number of research firms have changed their ratings and price targets for Uber Technologies (NYSE: UBER): 8/25/2026 – Uber Technologies had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $100.00 price target on the stock. 8/19/2026 – Uber Technologies had its “market outperform” rating reaffirmed by Citigroup Inc.. 8/13/2026 – […]

Spyre Therapeutics (NASDAQ: SYRE) has recently received a number of price target changes and ratings updates: 8/26/2026 – Spyre Therapeutics had its price target lowered by Deutsche Bank Aktiengesellschaft from $135.00 to $127.00. They now have a “buy” rating on the stock. 8/26/2026 – Spyre Therapeutics had its price target lowered by Wedbush from $130.00 […]

Several brokerages have updated their recommendations and price targets on shares of Ascendis Pharma A/S (NASDAQ: ASND) in the last few weeks: 8/18/2026 – Ascendis Pharma A/S is now covered by BMO Capital Markets. They set an “outperform” rating and a $319.00 price target on the stock. 8/18/2026 – Ascendis Pharma A/S is now covered […]